Acelink Therapeutics

Acelink Therapeutics is an innovative biopharmaceutical startup focused on developing safe and effective drugs to address the high unmet needs of human genetic diseases, including many rare diseases. The company's focus is on developing new therapies for genetic-related kidney diseases, such as Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD), and Fabry disease, enabling doctors to access safe and effective treatments for human genetic disorders.